(Repeats with no change to text)
Sept 6 (Reuters) - Verastem Inc said on Wednesday its drug to treat certain types of blood cancer met the main goal of a late-stage study.
The drug, duvelisib, showed a superior progression free survival rate than the current standard of care, ofatumumab, when tested on patients suffering from cancers that affect cells of the immune system, the company said.
Verastem said it intends to file for a marketing application for duvelisib in the first half of 2018. (Reporting by Tamara Mathias in Bengaluru; Editing by Savio D’Souza)
Our Standards: The Thomson Reuters Trust Principles.